If it’s magic, it might be fraud

In April 2009, Science retracted an article that described a technology that the authors had modestly called “MAGIC” for “MAGnetism-based Interaction Capture”. At the time, I wrote, in a post entitled “Nanoparticles: not magic after all“:

As a scientist who sometimes review papers, one of the key questions for me is: was it possible to detect the fraud at the time of submission? Can we learn something from this story about how better reviewing scientific papers. I had a fresh look at the original paper with this question in mind and the answer is not straightforward.

Reviewers do not have access to the lab books and primary evidence. In this case, the falsifications are not obvious: I don’t think that, as a reviewer, I would have suspected that the data were fabricated.

One thing however is striking: the paper reported extraordinary (magical?) results far from what was  at the time the state of the art. To take just one example, the technique viability supposed a perfect control on the cytosolic delivery of functional nanomaterials: 4 years later, this is still a field of active investigation and such a control is far from being routinely attained.  Yet, in the 2005 paper, claims over of such a control were accepted without the backing of a serious  experimental investigation, e.g. no electron microscopy images of the nanoparticles inside the cells were presented.

The paper went several steps ahead of the state of the art (and that’s why it was interesting for Science)… and some of the first steps were poorly (or not) documented, while the last step was documented with fabricated data. Maybe questioning these first steps would have allowed detecting the problem? or maybe not…

In February 2018, I asked on PubPeer the same question to the authors of a (then) recently published Nature Communication article – how did you get nanoparticles to the cytosol? The article reported fantastic (magic?) nanoparticles that would enter cancer cells, and, under IR irradiation, prevent the production of ATP thus making drug-resistant cancer cells vulnerable again. I did not get any response, but other comments followed. One asked another scientific question and in 2022 Actinopolyspora biskrensis found image duplications in Fig 7, S12 and S29. Now, eight years after publication, eight years after my unanswered question, four years after the duplications were found, the paper has been retracted following an institutional investigation.

I told that latter story recently on LinkedIn and noted that such cases demonstrated the benefit of being a PubPeer user (at the minimum of having installed the extension in your web browser). In a response to a PubPeer critic, I argued that my 2018 question (and the absence of an answer from the authors) as well as the observed duplications in figures were additional context valuable to readers for their own critical evaluation of the paper. Those readers may, for example, be PhD students whose project is partly based on that publication: without the PubPeer extension, they would not have been aware of those concerns and may have wasted months or years before realising the problems. I concluded my LinkedIn comment with a “tantalising question”:

What is the proportion of the thousands of articles where endosomal escape of nanoparticles is assumed without justification or explanation actually contains fraudulent data?

I cannot answer this question just yet (and probably won’t ever be able to do so quantitatively) but our post-publication peer review effort demonstrates its relevance since most articles that report the detection of intracellular cytosolic targets using nanoparticle probes do not demonstrate endosomal escape nor do they even mention the problem. We also identified image dupli cations and other serious issues in several of those articles. Further evidence of the role of data manipulation in the growth of this information bubble comes from the first results of our replication initiative.

From a practical point of view, systematically asking authors (on PubPeer or in peer review reports) to fill large methodological gaps would be a good practice for readers and peer reviewers of articles; it would contribute to identify common misconceptions sometimes based on, or amplified by, research misconduct.

Guest post: A Loss in Court, Really?

This is a guest post by Olivier Leclerc, CNRS senior researcher, Centre de Théorie et Analyse du Droit

It is only natural that Raphaël Lévy should feel he has lost in court, given that his case was dismissed by the administrative tribunal (Tribunal administratif de Montreuil, 3d chamber, 11 June 2026, no. 2309446). However, taking a broader view, the ruling reveals it actually contains a victory, a milestone, and a confirmation.

A victory: To my knowledge, this is the first time an administrative tribunal has recognized that a scientist reporting a breach of scientific integrity can be classified as a whistleblower under French protective legislation (Sapin 2 Act of December 9, 2016, amended in 2022), thereby benefiting from legal protections if they face retaliation. For my part, I had highlighted the relevance of this classification in an article published in Accountability in Research in 2023.

A milestone: Now, does the fact that Raphaël Lévy was the subject of a harassment complaint filed by the very person he reported for scientific misconduct constitute retaliation? In this ruling, the tribunal answered in the negative. However, this is a case-specific response, not a general precedent. Based on the case file, the tribunal found insufficient evidence to conclude that the harassment complaint against Lévy was abusive or malicious. It is possible that the tribunal’s observation—that Lévy did not consider it sufficient for the university to demand the correction of several articles and instead chose to publicize the misconduct—weighed in this assessment. In different circumstances, the outcome could well be different.

A confirmation: Following the harassment complaint against Lévy, the university launched an investigation to determine whether harassment had occurred. Lévy incurred legal fees to defend himself during this investigation and requested functional protection from his employer. The tribunal’s response here is entirely consistent with established practice: an employer who receives a harassment complaint must investigate it (failing to do so would be a fault); the resulting investigation is not a disciplinary procedure but merely a means to verify the alleged facts. Thus, the administrative tribunal noted that “such an investigation, initiated following a report from an employee, is a normal fact-finding measure intended to verify the alleged facts” and does not, in itself, warrant the granting of functional protection. Moreover, in this case, the administrative investigation concluded that the alleged harassment was not substantiated, and no disciplinary action was taken against Lévy. Unsurprisingly, functional protection is not granted to a civil servant simply because the administration is verifying whether reported harassment actually occurred. However—and this is far more interesting—the tribunal noted that the rector did grant Lévy functional protection “regarding actions that had the effect of degrading his working conditions and professional image.”

To sum up, the administrative tribunal establishes that:

  • Scientists who report breaches of scientific integrity can be classified as whistleblowers under French law and benefit from associated protections if they face retaliatory measures.
  • Being subjected to an internal investigation, even following a harassment complaint, is not inherently retaliatory. However, this could change if it were proven that the complaint was abusive or malicious. This assessment depends heavily on the specific circumstances of the case.
  • Functional protection is not automatically granted simply because a scientist is the subject of an internal investigation to verify harassment allegations. However, it may be granted if the individual suffers actual degradation or harm.

A loss in court

Update: see also, A loss in court, really? A guest post by Olivier Leclerc.

I am now officially a whistle-blower in the legal sense of the term.

More importantly, so are others who report scientific misconduct “without direct financial gain and in good faith”.

However, that does not entitle me (them) to much protection. That is my summary of the decision taken by the administrative court of Montreuil last week (Tribunal Administratif de Montreuil).

Context: reporting misconduct and facing retaliations. In February and April 2021, I reported a case of suspicions of data fabrications to the CNRS and to my employer, the Université Sorbonne Paris Nord (USPN). Many of the problems are so obvious that they take seconds to detect even for someone with zero expertise in the field. In spite of that, several years and two investigations were necessary to reach the obvious conclusion that many papers needed to be retracted (at–least–seven–still–need–to–be retracted). Whilst correction of science was slow, retaliations of various sorts started immediatelyagainst me. When the affair became public in December 2022, those retaliations took another dimension with three formal investigations opened… against me (one of those, particularly shameful, did not just target me, but also a colleague and two students we were co-supervising). All of those eventually concluded that there was no evidence of any wrongdoing. One of these investigation was a joint investigation (“enquête administrative”) by CNRS and USPN where I was accused (by the person who committed the misconduct) of moral harassment. I hired a lawyer to defend myself and I also requested the “protection fonctionnelle”, i.e. a protection that is due to civil servants by their employer and that covers legal fees that they would have to incur because of their professional activity. My request was turned down and I challenged this decision in court.

The court decision. The full document (in French) is available here. The key paragraph is below in French and then in English:

Si le signalement effectué par M. Lévy dans les conditions mentionnées au point 6, sans contrepartie financière directe et de bonne foi, qui visait à dénoncer une violation à la règle de l’intégrité scientifique posée par l’article L. 211-2 du code de la recherche, lui permet de se voir accorder le statut de lanceur d’alerte, il ne ressort pas des pièces du dossier que l’ouverture de l’enquête administrative diligentée à son encontre à la suite du signalement pour harcèlement moral dont il a fait l’objet et qui, ainsi qu’il a été dit au point 8, constitue une mesure normale d’instruction destinée à vérifier les faits allégués, constituerait une mesure de
rétorsion faisant suite à l’alerte lancée par M. Lévy. Il ne ressort pas davantage des pièces du dossier que la décision de refus de protection fonctionnelle attaquée aurait été prise en représailles. Par suite, M. Lévy n’est pas fondé à soutenir que le recteur de la région académique Ile-de-France, recteur de l’académie de Paris, aurait méconnu les dispositions protégeant les lanceurs d’alerte citées aux points 9 et 10.

If the report made by Mr Lévy under the conditions set out in point 6, without direct financial gain and in good faith, and which was intended to report a breach of the rule of scientific integrity laid down in Article L. 211-2 of the Research Code, entitles him to be granted the status of a whistleblower, it does not appear from the documents in the file that the opening of the administrative investigation conducted against him following the report of psychological harassment to which he was subjected – and which, as stated in point 8, constitutes a standard investigative measure intended to verify the alleged facts – constitutes a retaliatory measure in response to the report made by Mr Lévy. Nor does it appear from the documents in the file that the contested decision to refuse functional protection was taken in retaliation. Consequently, Mr Lévy is not justified in arguing that the Rector of the Île-de-France academic region, Rector of the Paris Academy, failed to comply with the provisions protecting whistleblowers cited in points 9 and 10. Translated with DeepL.com (free version) [and edited/approved by RL]

So, on one hand, this decision is important and positive. It seems to me (not a lawyer nor a legal scholar) that it clarifies a question that has been the focus of an article by Olivier Leclerc as well as a video and a note of the French office for scientific integrity: are you a whistle-blower (in a legal sense) if you report scientific misconduct? The answer is now yes.

On the other hand, if that whistle-blower status does not prevent your employer from starting proceedings against you, proceedings that are very clearly retaliatory and motivated by your whistle-blowing, then I am not so sure how useful the whistle-blower status really is…

A slide from Bert Seghers at the OFIS colloquim on 05/06/2026 "France plays above its weight in post-publication peer review" with pictures of Brandon Stell, Lonni Besançon, Raphaël Lévy, Guillaume Cabanac, Frédérique Bordignon, Cyril Labbé and Yagmur Ozturk" and the NanoBubbles logo

What was not discussed (enough) at the colloquium of the French Research Integrity Office

I attended last Friday the colloquium of the French Research Integrity Office which took place in the impressive and solemn settings of the Palais du Luxembourg, the French Senate. The meeting was opened by the director of the French Integrity office, Michel Dubois, and the president of the French Research Evaluation agency (HCERES), Coralie Chevallier, and two senators, David Ros (the current vice-president of the Parliamentary Office for Scientific and Technological Choices, OPECST) and Pierre Ouzoulias, who is at the origin of French legislation on Research integrity.

A third senator was in the programme, Karine Daniel, who was “rapporteur” of a law on academic freedom recently unanimously adopted in the Senate. Also in attendance and chairing the first session was Pierre Corvol, author of the famous 2016 report which has been the basis of most subsequent developments on this topic in France. Many other important actors of research integrity in France were presenting and some more were in the room. Antoine Petit, director of CNRS, was expected but was eventually replaced by the CNRS research integrity officer Claudine Pique.

The whole event has been recorded and will be available on the OFIS website at some point. I’ll list here a few things I found interesting but will then highlight the blind spots: what I consider as central issues, which were not (or minimally) discussed.

  • In his opening words, Michel Dubois noted the progress of the past few years but also rightly warned against institutional complacency (“autosatisfaction institutionnelle”).
  • Corine Chevallier emphasized the ongoing transition in research evaluation practices from one focused on outputs to one focused on the conditions in which research is done. The promise of her talk was an evaluation designed to promote good governance, collegiality, space for open critical discussion, a supportive working environment, and, institutions that respond adequately to issues such as breaches of research ethics or research integrity.
  • David Ros mentioned a recent round table held in the senate on the consequences of attacks on scientific integrity by the Trump administration (video and verbatim available here). He concluded his presentation by saying that scientific integrity was not just a condition of trust in science, but also a condition of trust in future political decisions.
  • Pierre Ouzoulias argued that scientists should communicate more about their methodologies so that people could better understand the difference between the opinion (of a politician or else) and a scientific claim. He concluded by an appeal to renew the link between the French republic and scientists with a reference to Irène Joliot Curie who was undersecretary of state for research (one of the first three women to be member of government) in 1936, at a time where women did not have the right to vote.
  • Pierre Corvol raised the issue of the administrative and legal status of the institutions’ integrity officers and more generally of the means they have (or lack) to fulfil their missions (this was developed further later in the day by Françoise Lantheaume and by Marc Léger). He considered that the investigation procedure was now accepted routine but that what happens (or not) following investigations still required more work (corrections and retractions, sanctions, etc). He highlighted three other issues to be debated: the impact of AI, reproducibility and education to research integrity at a younger age (from secondary school).
  • Pierre Léna and Sylvie Pommier talked about the “serment doctoral” (but I won’t).
  • Claudine Pique highlighted that it was very important to contribute to clean the scientific literature, which is quite paradoxical since that is precisely what the office she is heading is not doing adequately. Given the complete silence of CNRS on a major affair reported in Le Monde nearly two and a half years ago, I was also surprised by her claim that it was necessary to communicate about how investigations were done. It was nice though to hear her say that they had ongoing work inspired by LORIER to improve the diffusion of a scientific integrity culture within CNRS.
  • Françoise Lantheaume was president of the association of research integrity officers RESINT, 2023-2025. Her thoughtful contribution aimed to flesh out the real life and challenges faced by a research integrity officer in their diversity of environments, multiple duties (by far not limited to the investigation of specific cases). She concluded by stressing the devastating effects of the current research economy focused on productivity and competition, the fear of PhD students about reporting (even though more do contact the integrity officers), and the difficulties concerning what happens after the conclusion of an investigation by integrity officers (although unfortunately she did not have time to say more about that).
  • Bert Seghers (current president of the European Network of Research Integrity Offices) was given the difficult task of answering the question of the uniqueness (or not) of the French scientific integrity landscape compared to other European countries. He concluded with a couple of words on some of the unique “French excellence” that we have and should build on, and, well, that one was totally unexpected (see picture of the slide below)! Thank you Bert !
  • After lunch, Nicolas Fressengeas presided a session on new threats and new responses. Guillaume Cabanac talked about AI and you can already find his slides here. Chérifa Boukacem-Zeghmouri discussed the complexities of the publishing landscape. Olivier Emond, science journalist at France Info, explained how they work with scientists and how they try to ensure that the information they share is reliable. Clotilde Combe presented the results of a recent study about science and society (Le baromètre de l’esprit critique) ; in particular the questions related to trust in science, ethics and integrity.
  • The second and last session of the afternoon was presided by Olivier Descamps. Stéphanie Ruphy and Alain Israel presented INADIS, the new procedure, that should become accessible after summer, and were people (complainant or author of the alleged misconduct) unhappy about the outcome of an investigation (or unhappy about the absence of an investigation) will be able to ask for a second (first) opinion. Karine Daniel talked about the law on academic freedom. For her, the link with scientific integrity is strong : “la liberté scientifique est encadrée par l’intégrité scientifique”. I unfortunately had to leave during the presentation of Marc Léger and therefore also missed Michel Dubois’ closing words.

Not discussed at all: the cases. We spent the whole day talking about research integrity but no specific case of misconduct in France was ever mentioned (apart from my question about the protection of whistleblowers). Debating specific cases, what went right and what went wrong in the treatment of those cases, needs to happen in the laboratories and the universities (especially those home to those scandals) and in public spaces including in workshops and conferences about research integrity. Neither happens and therefore individually and collectively we fail to learn. There is another reason why it is important to be more open about specific cases, how they are investigated, and what specific corrective actions are taken. As Mahmud Farooque says (though in a different context):

And science gets especially lost when it forgets that public trust does not come from always sounding certain. It comes from being willing to correct oneself visibly.

Barely discussed: what happens after an investigation. It was alluded to by several speakers that there were issues there. But the problems were not stated very forcefully and the potential solutions were nowhere to be seen (apart maybe from the creation of INADIS, see above). What are the problems ? There are more, but here are two: 1) the correction of science does not happen, or happen too slowly and with a lack of transparency; 2) people who report misconduct are victims of retaliations (these happen also during the investigation of course); some, in particular PhD students or other young researchers, may feel that they just cannot report because they are too vulnerable and the institutions will not do anything to protect them (apart from anonymity which in many cases does not work). Those are difficult problems but by no means insoluble. If there was a real political will to solve them, it could be done.

A slide from Bert Seghers at the OFIS colloquim on 05/06/2026 "France plays above its weight in post-publication peer review" with pictures of Brandon Stell, Lonni Besançon, Raphaël Lévy, Guillaume Cabanac, Frédérique Bordignon, Cyril Labbé and Yagmur Ozturk" and the NanoBubbles logo
A slide from Bert Seghers at the OFIS colloquim on 05/06/2026

How to establish whether a disputed claim is true or false? Publication of the results of our first replication and call for others to replicate our work

How to establish whether a disputed claim is true or false? This is one of the questions at the centre of the ERC Synergy project NanoBubbles, which studies the barriers to the correction of science.

We focus on a controversy in bionanoscience: there are hundreds of scientific articles that report the specific detection of molecules or ions inside cells with nanoparticle probes, yet, when they enter cells, nanoparticles are largely sequestered in specific compartments where they cannot reach the target that they are supposed to detect. We are trying to understand, and maybe solve, this paradox.

To address this problem, we launched a replication initiative where we attempt to repeat the work described in the most cited articles. The replication team is composed of two post-doctoral researchers, Mustafa Gharib, a chemist, and Maha Said, a biologist, and myself. We include additional experiments to shed light on where the nanoparticles go after their entry into cells. In the case of the first replicated article, it did not go that far: after months of experimental work on the production and characterisation of the nanoparticle probes, we had to abort the replication when we realised that even outside of the cell, the nanoparticle probes prepared following the published protocols failed to detect their target (copper ions). We also discovered concerns regarding the integrity of the data. The original authors dispute our findings.

Often, when an experiment does not work, scientists just put the “negative data” in a drawer and move to another project, but in a replication project, that is obviously not an option. In fact, even before starting the experimental work, we had published as a preprint their entire protocols and experimental plans, which were peer-reviewed via the Peer Community In – Registered Reports platform, where the recommendation and signed peer reviews are available publicly. We have recently published a second preprint with their experimental results documenting the synthesis and properties of the synthesised nanoparticles. Like the first one, that preprint was evaluated via Peer Community In – Registered Reports. It will also be published in the scientific journal Royal Society Open Science.

Today, we are going one step further: we invite other scientists to replicate our replication and we will provide or fund the necessary chemicals and access to experimental platforms. We have opened a call with an independent international scientific advisory board who will be responsible for selecting the labs and help collate the obtained results. The Chair of the board, Cécilia Ménard-Moyon comments:

I think this call for further independent replications is timely, relevant, and needed. It is a good way to try to reach a conclusion about the disputed properties of those particles. I hope that colleagues across the world with the required expertise will engage in this original project and collaborative effort, which would represent an important step toward the democratization of replication initiatives.

Meanwhile, we are also working on a second replication. We have gone through the same process. The peer-reviewed protocols have been written, published and approved and the experiments are ongoing. Those nanoparticle probes should detect mRNAs inside cells (readers of this blog will be familiar with the NanoFlares). Although a few issues have already been detected, the results obtained so far on the synthesis and characterisation of the probes are close enough to the published results to enable us to move forward to the biology experiments.



LAUNCHING THE NANOBUBBLES REPLICATION INITATIVE

Said, M.; Gharib, M.; Lévy, R. Towards More Robust Nanobioscience: Launching the NanoBubbles Replication Initiative; Angewandte Chemie International Edition 2026 https://doi.org/10.1002/anie.202511631

In the news:

  • Nanoscience is latest discipline to embrace large-scale replication efforts, David Adam for Nature News, 17 February 2026
  • La réplication est un sport de combat, Lucile Veissier for TheMetaNews, 27 February 2026
  • De l’art difficile de reproduire des expériences scientifiques, David Larousserie pour Le Monde, 4 mars 2026


FIRST REPLICATION

Pre-registration
Said, M.; Gharib, M.; Zrig, S.; Lévy, R. Replication of “Carbon-Dot-Based Dual-Emission Nanohybrid Produces a Ratiometric Fluorescent Sensor for In Vivo Imaging of Cellular Copper Ions.” 2023. Open Science Framework https://doi.org/10.31219/osf.io/kf9qe. Peer review via PCI RR.

Registered report (stage 2)
Gharib, M.; Said, M.; Pons, T.; Hondow, N.; Zrig, S.; Lévy, R. Failed, Aborted Replication of “Carbon-Dot-Based Dual-Emission Nanohybrid Produces a Ratiometric Fluorescent Sensor for In Vivo Imaging of Cellular Copper Ions”. 2025 Open Science Framework doi:10.31219/osf.io/2x3hv_v3. Peer review via PCI RR.

Correspondence
Gharib, M.; Said, M.; Lévy, R. Correspondence on “Carbon-Dot-Based Dual-Emission Nanohybrid Produces a Ratiometric Fluorescent Sensor for In Vivo Imaging of Cellular Copper Ions”; Angewandte Chemie International Edition 2026 https://onlinelibrary.wiley.com/doi/epdf/10.1002/anie.4904466

Data sharing
Said, M.; Gharib, M.; Pons, T.; Hondow, N.; Zrig, S.; Lévy, R. (2025). FCS and TEM data of the replication of “Carbon-Dot-Based Dual-Emission Nanohybrid Produces a Ratiometric Fluorescent Sensor for In Vivo Imaging of Cellular Copper Ion” [Data set]. Zenodo. https://doi.org/10.5281/zenodo.15348672.

Chemical reaction and sample sharing
Gharib, M.; Said, M.; Zrig, S.; Lévy, R.; Reaction ID CRR-53507 ; Product Name N’-[2-[bis(2-pyridylmethyl)amino]ethyl]-N’-(2-pyridylmethyl)ethane-1,2-diamine ; Sample vial available. https://dx.doi.org/10.14272/reaction/SA-FUHFF-UHFFFADPSC-ICMHKEWHVR-UHFFFADPSC-NUHFF-NUHFF-NUHFF-ZZZ

SECOND REPLICATION

Pre-registration
Said, M.; Gharib, M.; Lévy, R. Replication of “Nano-Flares: Probes for Transfection and mRNA Detection in Living Cells” 2025. Open Science Framework https://doi.org/10.31219/osf.io/q8zsg_v3. Peer review via PCI RR.

Post doctoral Fellow: nanoparticle synthesis and characterisation for reproducible bionanoscience

*** PLEASE share this job advert ***

Scientific context:

The ERC Synergy NanoBubbles project is led by researchers from the Universities of Sorbonne Paris Nord, Maastricht, Grenoble-Alpes and Radboud, in collaboration with researchers from the CNRS, the University of Twente, IRIT and Ecole des Ponts. The project focuses on how, when and why science fails to correct itself. To understand how the correction of science works or fails, the NanoBubbles project combines approaches from the natural sciences (physics, chemistry, biology), engineering (natural language processing) and humanities and social sciences (linguistics, sociology, philosophy and history of science).

Within that project sits the first replication initiative in nanobioscience, where we also pioneer in this field open science approaches (protocol, data and sample sharing, registered reports, etc). The scientific focus is the paradox of endosomal escape, i.e. on articles that report the use of nanoparticles as sensors of cytosolic intracellular targets in spite of the probable endosomal entrapment of those probes after cell uptake. We have recently completed the first replication and are currently completing the experimental phase of the second replication [1-4].

The NanoBubbles replication team is hosted in Bobigny in team 4 of the Laboratory for Vascular Translational Science.

Objective:

We are seeking to recruit a chemist with expertise in nanoparticle synthesis, functionalisation and characterisation to join the replication team. The chemist will work with a biologist to contribute to the replication of further articles. The objective is to shed light on the reproducibility of those articles, help solve the paradox of endosomal escape and contribute to the improvement of methods and approaches in this field. Given the nature of this project, we are looking for a meticulous person motivated to adhere to, and even develop, rigorous scientific standards. That person should also be enthusiastic about communicating with colleagues of very different disciplines.

Qualifications we require: PhD in chemistry or material sciences

Experience:

  • Experience in nanoparticle synthesis and characterisation.
  • Experience in interactions of nanoparticles with biological systems.
  • Previous post-doctoral experience is valued but not mandatory.
  • Experience with handling and assembly of oligonucleotides is valued but not mandatory.

References:
[1] Mustafa Gharib, Maha Said, Thomas Pons, Nicole Hondow, Samia Zrig, and Raphaël Lévy. “Failed, Aborted Replication of ‘Carbon-Dot-Based Dual-Emission nanohybrid Produces a Ratiometric Fluorescent Sensor for
In Vivo Imaging of Cellular Copper Ions.’”
(2025) Preprint, Open Science Framework
[2] Maha Said, Mustafa Gharib, and Raphaël Lévy, Replication of “Nano-Flares: Probes for Transfection and mRNA Detection in Living Cells”, (2025) Preprint, Open Science Framework.
[3] Emily Linnane, Cécilia Menard-Moyon and Yuki Yamada “Unsuccessful Replication of Cellular Copper Ion Imaging Using Carbon Dots.” (2025) Peer Community in Registered Reports
[4] Cécilia Menard-Moyon “Are the Findings of ‘Nano-Flares: Probes for Transfection and mRNA Detection in Living Cells’ Reproducible?” (2025) Peer Community in Registered Reports

Field of research: Bionanoscience, chemistry

Skills: Nanoparticle synthesis, Nanoparticle functionalisation, Nanoparticle characterisation, Oligonucleotides handling

Where to apply: https://rubis.univ-spn.fr/offres/voir/209

Contacts: raphael.levy@univ-paris13.fr, nanobubbles@univ-paris13.fr

Application Deadline :
20 Feb 2026 – 00:00 (UTC)

Type of Contract : Temporary
Job Status : Full-time
Offer Starting Date : 20 April 2026
This job  is funded through the EU Research Framework Programme

End of contract : 28 may 2027

Work Location : Université Sorbonne Paris Nord; Laboratoire de Recherche Vasculaire Translationnelle (Laboratory for Vascular Translational Science); 1 rue Chablis, 93000 BOBIGNY

Welcome to the PhD games… and may the odds be ever in your favor!

Here is a short post to share some information about a talk I gave last week, for the third consecutive year, to over 200 new PhD students (and their supervisors) at the Welcome Day for new entrants 2025-2026 of the BioSPC doctoral School. The talk was entitled “Welcome to the PhD games… and may the odds be ever in your favor!”. I tried to make it both fun (it is a welcome day after all) and interactive, whilst still touching on pretty serious, dark and, yes, a little depressing at times, topics.

I used Wooclap to run polls during the talk. I can therefore tell you that in 2026, about 80% of this quite international cohort of PhD students have watched the movie the Hunger Games. Maybe, more interestingly, they respond “Curiosity”, “Passion”, and, well, many other things to the question “Why are you a scientist?”… The one who wrote “Sadism” was very fast to type and therefore their response was the first to appear, in huge letters, on the screen… thankfully that triggered a laugh and was not representative of the final picture 90 seconds later:

I noted that Katniss’ motivation to volunteer as a PhD student tribute was not curiosity nor passion, but sisterly love. My more serious point was to reflect on how what drives us to be scientists differ between people, but also how that changes during a career. Being aware of this strikes me as important to understand our research environment, including questions around ethics and integrity.

I also ask them what are the qualities of a good scientist and obtained a pretty nice set of responses, with “Curiosity” still being in the top 3, together with “Integrity” and “Patience”. This rare short video shows a PhD student in front of her Individual Monitoring Committee demonstrating perseverance, technical skills, creativity, courage, and a certain talent for regaining the attention of the committee when they do get bored (although I did not recommend the particular method used).

For the better and for the worse, scientific articles remain central to the lives and careers of scientists. So, I did ask them my favourite question: How do you know that a scientific article is good?

I could talk for a long time about that set of answers but I kept it short… reproducibility is great but hard or impossible to evaluate just by reading an article; impact factor of the journal? just no, absolutely not a measure of the quality of an article; citations? neither (mostly, a measure of attention; sometime these days a sign of manipulation – counterpoint: some methods papers are highly cited because the method works and is used). Peer review? well. I have breaking news. I concluded that there is no alternative to reading carefully and critically, and discussing it with others, students and post-doctoral researchers, supervisors and colleagues, and, of course, the entire world through the online journal club PubPeer.com.

This brought me towards the end of the talk, with a few more considerations about the frequency of scientific integrity breaches (based on a recent large scale study in France), negative data (Comics from The Upturned Microscope), p-hacking (Comics from xkcd).

Comments from attendees (and reader) are most than welcome.

Response of French research institutions to research misconduct remains inadequate

In March 2023, Dorothy Bishop and sixteen other internationally recognised leaders in the field of scientific integrity took the unusual step of sending an open letter to the CEO of CNRS to highlight that “the response [to unambiguous evidence of data manipulation] by institutions, publishers and funders is typically slow, opaque and inadequate, and is biased in favour of the accused, paying scant attention to the impact on those who use research, and placing whistleblowers in a difficult position”.

That letter was prompted by an article in the French newspaper Le Monde in December 2022 about a case of suspicions of data fabrications reported (by me) to CNRS and Université Sorbonne Paris Nord (USPN) in February and April 2021. Many of the problems are so obvious that they take seconds to detect even for someone with zero expertise in the field. This is, for example, the figure (published in ACS Omega, retracted in June 2025) that led me to look into the case in the first place. Can you see the problem?

Right. Those 3 red histograms, supposed to represent the size distribution of different nanoparticle samples, are in fact identical only differing by their X axis. Worse, between 2018 and 2021, the same histogram (or variants with minor modifications) was published 15 times spread between 8 articles including this one. And I discovered also re-use of other graphs as well as re-use of electron microscopy images between different publications.

Whilst it takes seconds to see the problem above, the secret investigation by integrity officers at CNRS and the Université Sorbonne Paris Nord (USPN) took ~18 months and eventually resulted in a one month suspension and the recommendation to correct (and not retract) a large number of publications. Some corrections, themselves often highly suspicious, happened in the summer of 2022. Remarkably, the journal editors were not informed by CNRS or USPN of the context of those authors-requested corrections at the time. A second investigation was triggered when other research integrity experts complained to the CNRS about the same (and additional) articles and their inappropriate corrections. Le Monde reported twice more on the case in April 2023 and May 2025 (see also Retraction Watch, March 2023). As we approach five years since my initial report (January 2021) and two and a half years since the open letter to CNRS mentioned above, the case has evolved in 2025 with a harsher sanction of two years suspension and a recommendation to retract 18 articles (14 actually retracted at the moment; 10 from the recommendation list and four others), including many which had already been corrected. For the first time in its history, the CNRS integrity office also published the recommendation on their website with the list of articles and the reasons why the articles should be retracted (“falsification”, “fraud”, “duplication of figures”, “highly improbable results”, etc).

The publication of this recommendation is a highly welcome step towards transparency, which was one of the requests of the open letter mentioned above. It is also in line with guidance published in July by the French Office of Scientific Integrity. This document includes other suggestions that institutions and their integrity officers should take into account, for example, stating explicitly that institutions must do everything they can to protect whistleblowers from retaliations and must inform journal editors (and other stakeholders) of the misconduct.

Yet there remains significant causes for concerns starting with how exactly and when will this guidance will be fully implemented. Some of Dorothy Bishop’s 2023 questions still remain unanswered with profound implications for treatment of misconduct cases. Those include: When problems are repeated across many papers, what are the criteria for concluding that there are “shortcomings and errors” rather than misconduct or fraud. When an investigation concludes that a publication contains material that is fabricated, falsified or plagiarised, what criteria are used to determine a recommendation that the paper be corrected, retracted, or other? What criteria are used to determine whether reports are confidential or public?  Do CNRS rules specify that a failure to report suspected research misconduct is itself misconduct?  What measures does CNRS take to protect whistleblowers?  

The response of the (current) CNRS integrity officer to questions asked on PubPeer about their own articles is another cause for concern. There is nothing wrong with being authors of articles which have comments on PubPeer (I have at least seven, including one with 349 comments which did set a record at the time). The important thing is the authors’ response to those comments. The officer did respond, which is good. But, in the comment thread where the concerns seem to be the most serious, after acknowledging the validity of the concerns, to the point that they write that several figures should be disregarded, they conclude: “Nevertheless, even disregarding the relevant sections of the figures, I believe that the other figures and the multiple approaches employed in this paper still demonstrate the molecular mimicry between VEGF and the HTLV-1 envelope protein“. The integrity officer has a major role in ensuring that the research conducted in their institution complies with the requirements of scientific integrity. They are also responsible for training others. Yet here, about their own research article that contains several problematic figures, they argue that their own belief that the main conclusions are valid is enough. Remarkably, their response to the question highlighted in bold above appears to be that no corrective action is necessary as long as the authors themselves are convinced that the main conclusions are still supported, even if the article contains figures that are so problematic that they should be disregarded.

The third cause for concern is the handling of another major case of suspicion of large scale data fabrication. Two years ago Le Monde reported that CNRS & Université of Lille had opened an investigation about 60 articles published by a University Prof and a Research Director at CNRS (the count on PubPeer is now at ~160 articles with comments still coming in). Two years later, neither of those institutions have communicated publicly about this case where over a hundred publications show signs highly indicative of falsification and fabrication of data. Those signs include a curve that changes colour in the middle of a graph as if it had been drawn by hand, bacterial colonies that were apparently painted on a picture of a plate taken from a commercial website, impossible Raman spectra, electron microscopy images re-used in multiple articles to represent different samples, etc, etc. What are the consequences of the absence of a public institutional response for the teams involved? For students on site? For researchers elsewhere? For the values of science that research and higher education institutions must defend? This silence has consequences. The institutions and the funders that supported this research cared enough about it first to sponsor it, and then to reward those researchers with prestigious awards and promotions. Now they must demonstrate that the integrity of the scientific record is a priority and be visibly proactive in 1) getting those articles retracted, and, 2) supporting a public discussion of this major scandal: what made it possible? how could it have been avoided? how could similar cases be handled better in the future? Analysing those cases is essential if we are collectively to learn and progress. Secrecy does not protect anyone, least of all research integrity.

PS: Below, the magically appearing bacterial colonies, reproduced from Marteen Van Kampen’s post at PubPeer.


Prize and lies

Updated 07/12/2025 with the quote from The Technion and 08/12/2025 with the FlashPoint Therapeutics press release.

Three years ago, I asked in a blog post here What do scientific prizes celebrate?

It was a reaction to false claims in press releases by the King Faisal Price and Northwestern University announcing the award of the 2023 King Faisal Prize in Medicine and Science to Chad Mirkin. One of the false claims was that spherical nucleic acids were the basis for more than 1,800 commercial products.

Well, new prize and new lies (actually mostly, the same lies repeated again and again). Here is an excerpt of the press release of Northwestern University about the Harvey Prize awarded to the same Chad Mirkin:

Seven SNA-based therapeutics are currently in human clinical trials and underpin more than 1,800 commercial products used globally.

The prize announcement on the webpage of The Technion, announcing the prize, makes the exact same false claim:

Seven SNA-based treatments are in human clinical trials, and SNAs are the basis for over 1,800 commercial products.

And so does the press release of FlashPoint Therapeutics (founded by Chad Mirkin):

His work has led to seven SNA-based therapeutics currently in human clinical trials and more than 1,800 commercial products used worldwide.

You can check my three years old post for details about the 1,800 commercial products recycled claim.

What about clinical trials? I believe that the true number of SNA-based therapeutics currently undergoing human clinical trials is not seven but zero.

I wrote to the author of the press release, Seth Zimmerman, the Associate Director of Marketing and Communications (International Institute for Nanotechnology, Northwestern University) asking:

Would you have any links or evidence (e.g. RCT registration numbers) for the following sentence in your article: ” Seven SNA-based therapeutics are currently in human clinical trials and underpin more than 1,800 commercial products used globally.” I believe that the real numbers are zero clinical trials currently underway and zero commercial products (maybe some Verigene consumables could be considered SNAs?), but if I am mistaken I would be glad to be corrected before writing about this.

He replied with a single sentence, insisting that the numbers are accurate, and claiming that they trace “by royalty and licensing payments”. I was not satisfied by this response and pushed further (see below) but did not get any further replies. Of course I welcome from anyone at Northwestern (or anyone else in the world) evidence that I am mistaken and would immediately correct the post if that was the case.

Dear Seth,

For most clinical trials, registration is required by law. They are not supposed to be traced by royalties and licensing payments but by NCT numbers. For example, here are some clinical trials for SNAs (not current; those have ended years ago):

  • NU-0129 to treat Glioblastoma or Gliosarcoma, Phase 1 –> NCT03020017 (25.05.2017-19.08.2020)
  • AST-008/cavrotolimod to treat Primarily advanced melanoma, Merkel cell carcinoma and cutaneous squamous cell carcinoma
    • Phase 1 –> NCT03086278 (20.10.2017-16.08.2018)
    • Phase 1b/2 –> NCT03684785 (13.12.2018-30.03.2022)

Could you please tell me what the NCTs of the 8 current clinical trials are? In the absence of NCTs, any other public information about those 8 current clinical trials would be appreciated (press releases, recruitment notices, anything really; clinical trials cannot be done in secret).

As for the 1,800 products, I would also like verifiable evidence. This should not be difficult. We are talking about 1,800 commercial products used globally: surely you can direct me to the links where I could buy at least some of those products. 

Best regards,

Raphaël